DLL3 was found to be heterogeneously expressed in the subtypes, with low expression levels in the SCLC-Y subtype and CD276 significantly higher expressed compared to DLL3 in both the SCLC-A (ASCL1) and SCLC-Y (YAP1) subtypes (Fig. 1B). This evidence concerns the gene DLL3 and small cell lung carcinoma.